PPD skin test enhances bacillus Calmette-Guerin Tx in bladder CA

May 16, 2018

(HealthDay)—For patients with non-muscle invasive bladder cancer, undergoing the purified protein derivative skin test prior to bacillus Calmette-Guérin therapy may have therapeutic impact, according to a study published in the June issue of The Journal of Urology.

Naoya Niwa, M.D., from the Keio University School of Medicine in Tokyo, and colleagues treated 498 patients with non-muscle with adjuvant bacillus Calmette-Guérin; 320 of the patients underwent the purified derivative skin test one to two weeks before therapy.

The researchers found that the mean ± standard deviation five-year recurrence-free survival rate was 66.6 ± 2.8 percent and 59.1 ± 4.1 percent for patients who did and did not undergo the purified protein derivative skin test, respectively (P = 0.048). There were no significant differences between the groups in progression-free survival. Significant independent associations with tumor recurrence were seen for a history of recurrence, multiple tumors, the bacillus Calmette-Guérin Connaught strain, seven or more bacillus Calmette-Guérin instillations, and undergoing the purified protein derivative skin test. Overall, 24.1 and 15.2 percent of who did and did not undergo the test, respectively, had major bacillus Calmette-Guérin-related side effects (P = 0.02).

"Combination therapy with bacillus Calmette-Guérin using the purified protein derivative skin may improve the oncologic outcomes of that therapy," the authors write.

Explore further: Bacillus Calmette-Guerin vaccine may reduce atopic dermatitis

More information: Abstract/Full Text

Related Stories

Bacillus Calmette-Guerin vaccine may reduce atopic dermatitis

September 25, 2017
(HealthDay)—Bacillus Calmette-Guérin (BCG) vaccination within seven days of birth may reduce the risk of allergic diseases, including atopic dermatitis, according to a study published online Sept. 20 in Allergy.

Phase III research represents potential shift in standard of care for bladder cancer

April 2, 2012
Use of the Connaught strain of bacillus Calmette-Guérin, an adjuvant immunotherapy used in the treatment of non-muscle-invasive bladder cancer, significantly reduced cancer recurrence compared with the Tice strain of ...

Heating chemotherapy drugs may improve bladder cancer treatment

May 17, 2016
Scientists have found that heating the chemotherapy drug mitomycin-C prior to using it for treating bladder cancer may radically improve its efficacy. The findings, published in the International Journal of Hyperthermia, ...

Clinical trials of VPM1002 as a tuberculosis vaccine in newborns

March 24, 2015
The only tuberculosis vaccine currently approved, the Bacillus Calmette-Guérin (BCG) vaccine, protects children from the most severe forms of the disease in most cases but does not provide protection against the most common ...

Clinical trial could lead to new bladder cancer drug

November 24, 2015
A bladder cancer drug tested in a University of Hawai'i Cancer Center clinical trial is getting closer to Food and Drug Administration (FDA) approval. The new drug, an interleukin 15 superagonist complex (ALT-803), combined ...

Recommended for you

Fully reprogrammed virus offers new hope as cancer treatment

May 25, 2018
A cancer treatment that can completely destroy cancer cells without affecting healthy cells could soon be a possibility, thanks to research led by Cardiff University.

Research could help fine-tune cancer treatment

May 25, 2018
Cancer therapies that cut off blood supply to a tumour could be more effective in combination with existing chemotherapeutic drugs—according to new research from the University of East Anglia.

Increasing physical activity linked to better immunity in breast cancer patients, study finds

May 25, 2018
A new study from the University of Toronto's Faculty of Kinesiology & Physical Education has found that moderate to vigorous physical activity may help regulate the levels of C-reactive protein – an important biomarker ...

Low-fat diet tied to better breast cancer survival

May 24, 2018
(HealthDay)—Breast cancer patients who adopted a low-fat diet were more likely to survive for at least a decade after diagnosis, compared to patients who ate fattier fare, new research shows.

A cascade of immune processes offers insights to triple-negative breast cancer

May 24, 2018
Cancer is crafty. To survive and thrive, tumors find a way of thwarting our body's natural systems.

By forming clots in tumors, immune cell aids lung cancer's spread

May 24, 2018
University of North Carolina Lineberger Comprehensive Cancer Center researchers have found that by helping to form clots within tumors, immune cells that flock to a particular type of lung cancer are actually building a foundation ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.